‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount
Executive Summary
Health technology assessment institute NICE has reversed its provisional rejection of Oxlumo for treating the rare disease, primary hyperoxaluria type 1.